anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The method for preventing the infectious complications following video thoracoscopy comprises video thoracoscopy providing all the required intraoperative procedures, the complete evacuation of the fluid from the pleural cavity, biopsy or puncture in avascular areas of the pathologic lesions, the use of the endoscopic containers for the removal of the resected tissues, the careful mechanical sanitization of the pleural cavity, the control of hemostasis and the leakage test with "water assay", and drainage of the pleural cavity at the end of the surgery. Preoperatively, 500 mg of Levofloxacin is administrated in one hour prior to the surgery. The surgical field is treated and covered with Loban antibacterial film. Intraoperatively, the pleural cavity is sanitized with Decasan solution in a volume of 1000 mL. Then Amicacin is instilled into the pleural cavity at a dose of 1000 mg. At the end of the surgery, the sanitization fibrobronchoscopy is provided. Postoperatively, Levofloxacin is used intravenously at a dose of 500 mg twice a day for the term of the drainage and for two days following the removal of the drainage.
This study will be performed on patients scheduled to undergo elective spinal surgery. The study will be a non-blinded, randomized clinical trial with a treatment arm and a control arm. After patient screening to determine eligibility and after patients are informed about the study and potential risks, all patients giving written informed consent will be randomized in a non-blinded manner in a 1:1 ratio to traditional preoperative patient counseling (control arm) or AR enhanced preoperative patient counseling (treatment arm). In the traditional preoperative patient counseling group, surgeons will explain the patients pathology and the surgery with only words and with or without pictures (MRI, CT, etc) and/or a generic 3D model. In the AR enhanced preoperative patient counseling group, the surgeon will have virtual, interactive models of the patients own anatomy projected through AR to show patients while describing the problem and how the surgery will be performed.

For all patients included within the treatment arm, the Medivis Surgical AR and AnatomyX platform will be deployed on the Microsoft Hololens 2 for AR image projection. When using Surgical AR, patient MRI and CT data will be accessed through the University of Pittsburgh Medical Centers Picture Archiving and Communication System (PACS) on the Medivis workstation. During preoperative consultation, the workstation will rapidly access the PACS system to pull the patients imaging and stream it to the Microsoft Hololens 2 AR-headset. For AnatomyX, a generic anatomic model is populated that can clearly present the anatomy involved in a procedure and also allows for a shared interactive space in which the patient, patient family, and surgeon can exist.
Urinary iodine will be measured at one point in time in school children aged 6-12. A sample of salt used at home and schools will be collected to estimate iodine levels.
The invention discloses a method used for separating and purifying a eupatorium odoratum flavonoid substance by using HZ816 macroporous adsorption resin. According to the invention, the flavonoid substance is extracted from eupatorium odoratum by using edible ethanol, such that a crude extract is obtained; the crude extract is separated and purified by using HZ816 macroporous adsorption resin, such that an extract of an eupatorium odoratum flavonoid substance is obtained. With the method provided by the invention, the eupatorium odoratum flavonoid substance is safely extracted and separated with no toxicity by using edible ethanol, such that a harmful matter is turned into a valuable matter. With the method provided by the invention, safe and effective eupatorium odoratum flavonoid substance extracts with different purity specifications can be industrially produced. With the method, eupatorium odoratum resources can be safely, conveniently, reasonably, and economically utilized with higher values, and industrialized productions of product series can be actually realized. With the method, the concept of green chemical production and the strategy of virtuous circular economy can be realized.
Surgical resection offers the only hope of cure for pancreatic adenocarcinoma. While perioperative mortality rates have declined in recent years, pancreatic resection is still associated with significant postoperative malnutrition, maldigestion, and glucose intolerance, mostly as a result of pancreatic insufficiency. Quantifying individual pancreatic function remains a challenge, but is essential in improving the survival and quality of life of pancreatic cancer patients. Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in pancreatic ducts, as well as functional secretory capacity of the gland. The aim of our study is to evaluate S-MRCP as a means to evaluate for pancreatic exocrine insufficiency. This will be a prospective study of twelve patients who have undergone pancreatic resection and who have symptoms of abdominal pain, steatorrhea or weight loss. We will be comparing quantitative parameters of S-MRCP (maximal change in pancreatic duct diameter and volume before and after secretin administration) with endoscopic pancreatic function testing (maximal bicarbonate concentration in duodenal aspirate after secretin administration).
Five sessions of unilateral auricular acupuncture were applied alternately to the right and left ears, once a week, to the intensive care nurses in the semi-permanent needle group. Semi-permanent needles placed on the acupuncture points of the nurses' ears remained for one week with adhesive tapes. In the sessions in the following weeks, semi-permanent needles were replaced with new ones. Shen men (TF4), Sympathetic (AH6a), Lung, Liver (CO12) Kidney point (CO10) were applied to five specific points in the ear in accordance with the NADA protocol.
FIELD: emulsions. SUBSTANCE: method involves stirring an aqueous and oily phase and preparing highly concentrated emulsion at volume content of dispersed phase above coefficient of maximal ball package - above 0.74%. Then the prepared emulsion is diluted with water up to content of dispersed phase below this index, preferably, below 0.66%. Size of the dispersed phase drops is less 0.5-1 mc. Emulsion is used for preparing ointment, cream, latex. EFFECT: improved method of preparing. 2 cl
Participants randomized to the intervention group will complete ePRO symptom severity scores on the PSA-Lung questionnaire via the smartphone app on discharge and post-discharge days 3, 7, 14, 21, 28. Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management.
The research team members will not have contact with the Special Olympic athletes. Parents and coaches will be the only individuals who have contact with the athletes. Participants will be assured that their participation is completely voluntary. If they agree to participate in the research an informed assest form will be explained by a parent, guardian, or coach and they will be asked to sign it. Parents will be asked to sign a consent form for their child's participation in the study. Coaches will administer the SCOPE as a pre/post-test outcome measure. Parents will submit the Parent form of the SCOPE and the coaches will submit the SCOPE Clinical Data Summary Form. All data will be de-identified and sent in form the coaches. The TWU special olympics research team will compile de-identified data from a pre-test and post-test utilizing the SCOPE. A codebook that links the ID number with the participants will be kept by the coaches. The research team may be able to trace assented data collected through the TWU data collection protocol back to the coaches. Participating athletes will not be contacted by the PI and no contact information will be collected. In the case of an unexpected or adverse event, or if the participants request to be contacted, attempts may be made to find the subjects contact information through the coaches. De-identified data collected by the TWU Special Olympic research team or other Key Research personnel will be stored on a password protected computer or in a locked file cabinet in a locked office in the department of occupational therapy at Texas Woman's University in Houston. The raw data collected will not be made available to anyone other than the PI and immediate study research personnel. Data is entered into the database using the ID number, and the computer database is password protected. The raw data is not going to be shared. The data will be kept in a locked file cabinet within the research office of the databases destroyed 4 years after the end of the study. The results of the analysis, which may include information from the data, will be kept on a password secure computer indefinitely. The data collected from pre-tests and post-tests will then be compiled and analyzed.
Patients aged 18 years and older admitted in a hospital in Brabant after a trauma, independent of severity or type of injury are included in the study. Patients who decease during hospital stay or transferred to another hospital outside the borders of trauma region Brabant will be excluded. Socio-demographic characteristics, functional and psychological outcome and Health Related Quality of Life (HRQoL) shortly after trauma will be measured. Subsequently the same items will be measured after 1, 3, 6, 12 and 24 months. Outcomes will be assessed using questionnaires. The primary outcome parameters are: short and long term HRQoL, functional and psychological outcome, and Healthcare and societal costs in injured patients. Secondary outcome measures are Return to Work and health care consumption.
Orthodontic treatment with fixed appliances has the potential to induce pain in patients. At the beginning of treatment, the orthodontist must determine which initial orthodontic archwire to insert. Among the more popular choices for initial leveling and aligning of the dental arches are small-sized, round-diameter nickel-titanium archwires. Various types of nickel-titanium (NiTi) archwires exist including stabilized martensitic wires (ie classic Nitinol), active austenitic wires (superelastic NiTi) and active martensitic wires (thermoelastic NiTi). The efficacy of these wire types has been heavily researched with no significant differences in the alignment timing of the dentition (treatment time to reach the final archwire). Pain differences from these wires has been inconclusive from conflicting past studies. It is of critical importance to determine whether one or more of these archwires leads to more discomfort for the patient than the others.
PROBLEM TO BE SOLVED: To prepare a composition for an oral cavity excellent in retention of a medicinal ingredient effective for oral hygiene in a tissue in the oral cavity for a long period by formulating a specific polymer therein. SOLUTION: This composition for an oral cavity is prepared by formulating a polymer containing isopropylacrylamide as a monomer unit in the polymer chain therein. Polyisopropylacrylamide, a copolymer of the isopropylacrylamide and a monomer copolymerizable therewith, e.g. a copolymer of the isopropylacrylamide and a monomer represented by formula I or II (R<1> is H or methyl; R<2> and R<3> are each H or an alkyl) and a copolymer of the isopropylacrylamide and butyl methacrylate are cited as the polymer containing the isopropylacrylamide as the monomer unit. The amount of the polymer formulated in the composition for the oral cavity is preferably 0.1-5 wt.%. Furthermore, the isopropylacrylamide has excellent actions on removal of bacterial plaques from teeth.
Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
The invention relates to a stable pharmaceutical composition of a solution for per oral drops containing metamizole sodium monohydrate. The solution is with constant composition during the shelf lifeand has acceptable for the user organoleptic properties. The composition according to the invention contains 500 mg/ml active substance metamizole sodium monohydrate, 75-125 m? citrate buffer with capacity of ?? 7 to 8, a system for taste masking which is a mixture of 2.5% w/v sodium cyclamate, 0.3% w/v saccharin sodium and 0.3 % w/v powder with strawberry flavor and purified water to 1 ml.
Methylphenidate hydrochloride extended-release tablets uses osmotic pressure to deliver methylphenidate HCl at a controlled rate. The system, which resembles a conventional tablet in appearance, comprises an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components. There is a precision-laser drilled orifice on the drug-layer end of the tablet. In an aqueous environment, such as the gastrointestinal tract, the drug overcoat dissolves within one hour, providing an initial dose of methylphenidate. Water permeates through the membrane into the tablet core. As the osmotically active polymer excipients expand, methylphenidate is released through the orifice. The membrane controls the rate at which water enters the tablet core, which in turn controls drug delivery. Furthermore, the drug release rate from the system increases with time over a period of 6 to 7 hours due to the drug-concentration gradient incorporated into the two drug layers of methylphenidate hydrochloride extended-release tablets. The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the stool as a tablet shell along with insoluble core components. It is possible that methylphenidate hydrochloride extended-release tablets may be visible on abdominal x-rays under certain circumstances, especially when digital enhancing techniques are utilized.
The pro-inflammatory immune microenvironment in the localized lesion areas and the absence of DNA damage repair mechanisms in endothelial cells serve as essential accelerating factors in the development of atherosclerosis. The lack of targeted therapeutic strategies represents a significant limitation in the efficacy of therapeutic agents for atherosclerosis. In this study, Genetically engineered SNHG12-loaded cerium-macrophage exosomes (Ce-Exo) are designed as atherosclerosis-targeting agents. In vivo studies demonstrated that Ce-Exo exhibited multivalent targeting properties for macrophages, with a 4.1-fold higher atherosclerotic plaque-aggregation ability than that of the control drugs. This suggests that Ce-Exo has a higher homing capacity and deeper penetration into the atherosclerotic plaque. In apolipoprotein E-deficient mice, Ce-Exo found to effectively remodel the immune microenvironment in the lesion area, repair endothelial cell damage, and inhibit the development of atherosclerosis. This study provides a novel approach to the treatment of atherosclerosis and demonstrates the potential of cell-derived drug carriers in biomedicine.
FIELD: medicine, immunology. SUBSTANCE: agent has complex of immunopeptides obtained by culturing the stimulated leukocytes from peripheral blood of mammals followed by isolation of the end agent. Pig or human leukocytes are used as the parent raw for the claimed agent preparing. Leukocytes are stimulated with substance of the group of mitogenic lectins, in part, phytohemagglutinin or concanavalin A. Then lectin is removed from the system by centrifugation. Culturing is carried out for 20-24 h, supernatant is obtained and the end agent (molecular mass is 40 kDa or less) is isolated from supernatant by fractionation. The end agent can be obtained in lyophilized form. Agent activates cells of phagocytic order, regulates processes of inflammation and regeneration and showing promise for treatment and prophylaxis of inflammatory diseases in persons with damaged immune system. Invention can be used for preparing the novel immunostimulating agent based on the complex of natural immunopeptides regulating processes of inflammation and regeneration. EFFECT: improved method of preparing, enhanced effectiveness of agent. 4 cl, 5 dwg
From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
Non-alcoholic steatohepatitis (NASH) is becoming an increasingly serious global health threat, distinguished by hepatic lipid accumulation, inflammation, and fibrosis. There is a lack of approved pharmaceutical interventions for this disease, highlighting the urgent need for effective treatment. This study explores the hepatoprotective potential of 6-shogaol, a natural compound derived from ginger, in a methionine- and choline-deficient (MCD) dietary mouse model of NASH. Male C57BL/6J mice were subjected to the MCD diet for 4 weeks to induce NASH, with concurrent intraperitoneal administration of 6-shogaol (20 mg/kg) three times a week. While 6-shogaol did not impact body weight, liver weight, or hepatic lipid accumulation, it effectively mitigated liver injury, inflammation, and fibrosis in MCD diet-fed mice. Mechanistically, 6-shogaol inhibited lipid and DNA oxidation, restored hepatic glutathione levels, and regulated the expression of pro-oxidant and antioxidant enzymes. Furthermore, 6-shogaol inhibited apoptosis and necroptosis, as indicated by a decrease in TUNEL-stained cells and downregulation of apoptosis- and necroptosis-associated proteins. Additionally, 6-shogaol alleviated endoplasmic reticulum (ER) stress, as demonstrated by decreased expression of molecules associated with unfolded protein response pathways. These findings underscore the potential of 6-shogaol as a therapeutic intervention for NASH by targeting pathways related to oxidative stress, cell death, and ER stress.
Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Participants will receive 50% rMT iTBS over left DLPFC in this arm. The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
PURPOSE:To obtain an agent for alleviating acquired immune deficiency syndrome, harmless to human body, showing excellent activity, containing at least one of D-phenylalanine and L-phenylalanine. CONSTITUTION:The aimed substance containing at least one of D-phenylalanine and L-phenylalanine. The aimed substance can be prepared into a form such as powder, etc. A dose is 10mg based on 1kg weight daily. D-Phenylalanine and L-phenylalanine are amino acids readily obtained by subjecting phenylalanine prepared by synthesis to optical resolution. D-Phenylalanine and L-phenylalanine inhibit multiplication of AIDS virus in T-cell by raising activity of T-cell and are effective for preventing and treating AIDS.
A hybrid detection model may be used for breast cancer detection. A system can identify a region of interest on a received mammogram. The region of interest may have a particular level of grey at each pixel of the image. A morphological and entropy filter may then each be applied to the region of interest. Based on the filters, the system may generate a hybrid result that is the average of a combination of the two filters. The system may then segment the region of interest using a selected clustering algorithm.
This study compared milk replacer either remaining unsupplemented (CON) or supplemented with 0.5 g L-carnitine plus 16.7 g L-arginine/kg (CarArg) and fed to 48 low-birth weight (L-BtW) artificially reared piglets (24 per group) from days 7 to 28 of age. Eight farrowing series were needed to complete the study. On day 28, the lightest piglets were slaughtered, and the heaviest pigs were weaned. The heaviest pigs were weaned on day 28 and offered free access to a starter (weaning to 25 kg body weight [BW]), grower (25 to 60 kg BW), and finisher diet (60 to 96 kg BW on day 170 of age). After euthanization on days 28 and 170, blood was sampled for assessment of serum metabolite and hormone concentrations, and the semitendinosus muscle (STM) was weighed, and later subjected to enzyme activity analysis and assessment of myofiber characteristics. In the 170-d-old pigs carcass and meat quality traits were assessed. Growth data were analyzed accordingtoatwo-way analysis of variance (ANOVA), with dietary treatment and farrowing series as fixed effects, while remaining data were analyzed with dietary treatment, sex, their interaction, and farrowing series as main factors. Dietary treatments affected (P ≤ 0.049) muscle enzyme activity at both day 28, with greater citrate synthase (CS) and LDH activities and lower HAD:CS ratio in STM light portion, and lower LDH:CS ratio in STM dark portion, and 170 of age with lower HAD:CS ratio. In the starter period, CarArg pigs had greater average daily gain (P = 0.021) and average daily feed intake (P = 0.010). At slaughter, these pigs had lower (P = 0.013) glucose and greater (P = 0.022) urea serum concentrations. However, supplementing the milk replacer with carnitine and arginine had no long-term effects on growth performance, carcass composition, and meat quality of L-BtW pigs. In addition, muscle morphology and myofiber-related properties remained unaffected by the supplementation.
There is a clear need for improved therapy in ANCA associated vasculitis where current treatments are toxic and contribute to poor outcomes. Conventional therapy combines cyclophosphamide with prednisolone but is associated with severe adverse events in 35%, early mortality, malignancy and infertility. Mycophenolate mofetil (MMF) is a newer immunosuppressive drug which has superior efficacy to azathioprine in solid organ transplantation. MMF is an effective alternative to cyclophosphamide in lupus nephritis. Open label studies and retrospective surveys point to the efficacy and low toxicity of MMF in vasculitis.

We hypothesise that MMF not be less effective than cyclophosphamide for remission induction in AASV. 140 new patients will be randomised to MMF 3g/day or a European consensus intravenous cyclophosphamide regimen, with the same prednisolone dosing. Following a six month induction course all patients will receive consensus remission maintenance treatment with azathioprine and prednisolone. The primary end-point will be remission rate by six months, secondary end-points include relapse rate at 18 months and safety. The trial will be conducted in 10 countries by members of the European Vasculitis Study Group (EUVAS). The trial duration will be 42 months (24 months recruitment, 18 months follow up).